Gene delivery using ultrasound contrast agents

Evan C Unger, Evan M Hersh, Mani Vannan, Thomas McCreery

Research output: Contribution to journalArticle

139 Citations (Scopus)

Abstract

With the human genome product and continuing advances in molecular biology many therapeutic genes have been discovered. In the cardiovascular system, gene therapy has the potential to improve myocardial vascularization and ameliorate congestive heart failure. For successful development of clinical gene therapy, however, effective gene delivery vectors are needed. Ultrasound contrast agents can be used to develop new, more effective vectors for gene delivery. Ultrasound contrast agents lower the threshold for cavitation by ultrasound energy. Using physical properties of microbubbles and coating materials, genetic drugs have been incorporated into ultrasound contrast agents. Gene-bearing microbubbles can be injected IV and ultrasound energy applied to the target region. As the microbubbles enter the region of insonation, the microbubbles cavitate, locally releasing DNA. Cavitation also likely causes a local shockwave that improves cellular uptake of DNA. With transthoracic ultrasound, using commercially available diagnostic ultrasound system and an IV injection of gene-bearing microbubbles, high levels of transgene expression are observed in the insonated region of the myocardium. This new technology using microbubbles and ultrasound for gene delivery merits further study and development.

Original languageEnglish (US)
Pages (from-to)355-361
Number of pages7
JournalEchocardiography
Volume18
Issue number4
StatePublished - 2001

Fingerprint

Microbubbles
Contrast Media
Genes
Genetic Therapy
DNA
Human Genome
Cardiovascular System
Transgenes
Molecular Biology
Ultrasonography
Myocardium
Heart Failure
Technology
Injections
Pharmaceutical Preparations

Keywords

  • Gene therapy
  • Microbubbles
  • Ultrasound contrast agents

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Radiology Nuclear Medicine and imaging

Cite this

Gene delivery using ultrasound contrast agents. / Unger, Evan C; Hersh, Evan M; Vannan, Mani; McCreery, Thomas.

In: Echocardiography, Vol. 18, No. 4, 2001, p. 355-361.

Research output: Contribution to journalArticle

Unger, EC, Hersh, EM, Vannan, M & McCreery, T 2001, 'Gene delivery using ultrasound contrast agents', Echocardiography, vol. 18, no. 4, pp. 355-361.
Unger, Evan C ; Hersh, Evan M ; Vannan, Mani ; McCreery, Thomas. / Gene delivery using ultrasound contrast agents. In: Echocardiography. 2001 ; Vol. 18, No. 4. pp. 355-361.
@article{fd3551c74bfc472ca445bfb53c304db9,
title = "Gene delivery using ultrasound contrast agents",
abstract = "With the human genome product and continuing advances in molecular biology many therapeutic genes have been discovered. In the cardiovascular system, gene therapy has the potential to improve myocardial vascularization and ameliorate congestive heart failure. For successful development of clinical gene therapy, however, effective gene delivery vectors are needed. Ultrasound contrast agents can be used to develop new, more effective vectors for gene delivery. Ultrasound contrast agents lower the threshold for cavitation by ultrasound energy. Using physical properties of microbubbles and coating materials, genetic drugs have been incorporated into ultrasound contrast agents. Gene-bearing microbubbles can be injected IV and ultrasound energy applied to the target region. As the microbubbles enter the region of insonation, the microbubbles cavitate, locally releasing DNA. Cavitation also likely causes a local shockwave that improves cellular uptake of DNA. With transthoracic ultrasound, using commercially available diagnostic ultrasound system and an IV injection of gene-bearing microbubbles, high levels of transgene expression are observed in the insonated region of the myocardium. This new technology using microbubbles and ultrasound for gene delivery merits further study and development.",
keywords = "Gene therapy, Microbubbles, Ultrasound contrast agents",
author = "Unger, {Evan C} and Hersh, {Evan M} and Mani Vannan and Thomas McCreery",
year = "2001",
language = "English (US)",
volume = "18",
pages = "355--361",
journal = "Echocardiography",
issn = "0742-2822",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Gene delivery using ultrasound contrast agents

AU - Unger, Evan C

AU - Hersh, Evan M

AU - Vannan, Mani

AU - McCreery, Thomas

PY - 2001

Y1 - 2001

N2 - With the human genome product and continuing advances in molecular biology many therapeutic genes have been discovered. In the cardiovascular system, gene therapy has the potential to improve myocardial vascularization and ameliorate congestive heart failure. For successful development of clinical gene therapy, however, effective gene delivery vectors are needed. Ultrasound contrast agents can be used to develop new, more effective vectors for gene delivery. Ultrasound contrast agents lower the threshold for cavitation by ultrasound energy. Using physical properties of microbubbles and coating materials, genetic drugs have been incorporated into ultrasound contrast agents. Gene-bearing microbubbles can be injected IV and ultrasound energy applied to the target region. As the microbubbles enter the region of insonation, the microbubbles cavitate, locally releasing DNA. Cavitation also likely causes a local shockwave that improves cellular uptake of DNA. With transthoracic ultrasound, using commercially available diagnostic ultrasound system and an IV injection of gene-bearing microbubbles, high levels of transgene expression are observed in the insonated region of the myocardium. This new technology using microbubbles and ultrasound for gene delivery merits further study and development.

AB - With the human genome product and continuing advances in molecular biology many therapeutic genes have been discovered. In the cardiovascular system, gene therapy has the potential to improve myocardial vascularization and ameliorate congestive heart failure. For successful development of clinical gene therapy, however, effective gene delivery vectors are needed. Ultrasound contrast agents can be used to develop new, more effective vectors for gene delivery. Ultrasound contrast agents lower the threshold for cavitation by ultrasound energy. Using physical properties of microbubbles and coating materials, genetic drugs have been incorporated into ultrasound contrast agents. Gene-bearing microbubbles can be injected IV and ultrasound energy applied to the target region. As the microbubbles enter the region of insonation, the microbubbles cavitate, locally releasing DNA. Cavitation also likely causes a local shockwave that improves cellular uptake of DNA. With transthoracic ultrasound, using commercially available diagnostic ultrasound system and an IV injection of gene-bearing microbubbles, high levels of transgene expression are observed in the insonated region of the myocardium. This new technology using microbubbles and ultrasound for gene delivery merits further study and development.

KW - Gene therapy

KW - Microbubbles

KW - Ultrasound contrast agents

UR - http://www.scopus.com/inward/record.url?scp=0034956573&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034956573&partnerID=8YFLogxK

M3 - Article

C2 - 11415509

AN - SCOPUS:0034956573

VL - 18

SP - 355

EP - 361

JO - Echocardiography

JF - Echocardiography

SN - 0742-2822

IS - 4

ER -